The use of Bifidobacterium (mixed) probiotics for diverticulitis is primarily supported by emerging scientific evidence, though the overall quality and quantity of evidence is limited and not yet conclusive. Diverticulitis involves inflammation or infection of diverticula (small pouches) in the colon. Some studies suggest that disruption of the gut microbiota may contribute to the pathogenesis of diverticular disease, and probiotics like Bifidobacterium may help restore microbial balance, reduce inflammation, and support intestinal barrier function.

Clinical studies examining probiotics in diverticular disease are mostly small, heterogeneous, and often combine Bifidobacterium with other probiotic strains (such as Lactobacillus). Some randomized controlled trials and reviews (e.g., Guglielmetti et al., 2011; Tursi et al., 2016) report reductions in symptoms such as abdominal pain and bloating in patients with symptomatic uncomplicated diverticular disease, a related but distinct condition from acute diverticulitis. Evidence for preventing recurrence of diverticulitis or for treating acute diverticulitis is less robust. Limited data suggest a possible benefit in reducing inflammation and improving gut health, but larger and more rigorous trials are needed.

In summary, while there is some scientific rationale and preliminary clinical evidence for the use of Bifidobacterium probiotics in diverticular disease management, the direct evidence for their efficacy in diverticulitis specifically is modest. Most guidelines still recommend antibiotics and dietary management as first-line therapies, with probiotics considered as adjuncts in select cases.